Beginning December 1, 2019, health care professionals who handle hazardous drugs will be required to comply with stricter standards. The guidance, issued by the United States Pharmacopeia (USP), will help ensure greater safety for the workers who handle hazardous drugs.
Health care organizations are encouraged to be proactive in their approach to USP <800> so they are prepared for the enforcement of the standards come December.
One drug that will require more specialized handling practices is the potassium-sparing diuretic spironolactone. Spironolactone tablets are often compounded into liquid oral suspensions for patients who have difficulty swallowing, but now there is an alternative option. CaroSpir is the first and only FDA-approved oral suspension of spironolactone, and it does not have a black box warning. The guidelines for handling hazardous drugs like spironolactone tablets do not apply to CaroSpir.
To learn more about the enforcement of USP <800>, read this article from Hospital Safety Center:
To learn more about CaroSpir, please visit www.CaroSpir.com.